JPS5940835B2 - alcohol derivative - Google Patents
alcohol derivativeInfo
- Publication number
- JPS5940835B2 JPS5940835B2 JP58195048A JP19504883A JPS5940835B2 JP S5940835 B2 JPS5940835 B2 JP S5940835B2 JP 58195048 A JP58195048 A JP 58195048A JP 19504883 A JP19504883 A JP 19504883A JP S5940835 B2 JPS5940835 B2 JP S5940835B2
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- compound
- formula
- alcohol derivative
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】
本発明は一般式
式中、Aは低級アルキレンを、Xは水素、低級アルキル
カルボニルを示す。DETAILED DESCRIPTION OF THE INVENTION In the general formula of the present invention, A represents lower alkylene, and X represents hydrogen or lower alkylcarbonyl.
)で表わされるアルコール誘導体またはその酸付加塩に
関する。) or its acid addition salt.
上記定義中、低級アルキルはメチル、エチルなどを、低
級アルキレンはメチレン、エチレン、トリメチレン、プ
ロピレンなどを示す。In the above definition, lower alkyl refers to methyl, ethyl, etc., and lower alkylene refers to methylene, ethylene, trimethylene, propylene, etc.
本発明によれば、一般式(I)で表わされる化合物は一
般式Hal−CH2COOA−O−X(■)〔式中、A
、Xは前記と同義であり、Halはハロゲン(塩素、臭
素など)を示す。According to the present invention, the compound represented by the general formula (I) has the general formula Hal-CH2COOA-O-X (■) [wherein A
, X have the same meanings as above, and Hal represents halogen (chlorine, bromine, etc.).
〕で表わされる化合物と式
ゴNH2(■)
で表わされる化合物とを反応させることにより製造され
る。It is produced by reacting a compound represented by ] with a compound represented by the formula NH2 (■).
反応は好ましくはメタノール、エタノールなどのアルコ
ール系溶媒中、還流下に行われる。The reaction is preferably carried out in an alcoholic solvent such as methanol or ethanol under reflux.
その際に脱酸剤として式(■)の化合物を一般式(■)
の化合物に対して2倍モル良用いるが、炭酸水素ナトリ
ウム、炭酸ナトリウム、炭酸カリウム、水酸化ナトリウ
ムまたは水酸化カリウムを加えてもよい。また、一般式
(I)のxが水素の化合物はXが低級アルキルカルボニ
ルである化合物を加水分解することによつて製造される
。At that time, the compound of formula (■) is used as a deoxidizing agent.
Although twice the molar amount of the compound is used, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, or potassium hydroxide may be added. Further, a compound in the general formula (I) in which x is hydrogen is produced by hydrolyzing a compound in which X is lower alkylcarbonyl.
この反応は酸性条件下(塩酸、臭化水素酸、硫門酸など
)または好ましくは塩基性条件下(水酸化ナトリウム、
水酸化カリウムなど)に行われる。This reaction is carried out under acidic conditions (hydrochloric acid, hydrobromic acid, sulfuric acid, etc.) or preferably under basic conditions (sodium hydroxide,
potassium hydroxide, etc.).
さらに、一般式(I)の化合物は、一般式・R−
(式中、Rは水素、低級アルキル、低級アルコキシを、
Zは単結合または低級アルキレンを示す。Furthermore, the compound of the general formula (I) can be prepared by the general formula R- (wherein R is hydrogen, lower alkyl, lower alkoxy,
Z represents a single bond or lower alkylene.
)で表わされる化合物を還元反応に付すことによつても
得られる。反応は、Rが水素、低級アルキルの場合は、
たとえばメタノール、エタノールなどの溶媒中、水素化
ホウ素ナトリウムを用いることにより、またRが低級ア
ルコキシの場合は、たとえばテトラヒドロフラン中水素
化アルミニウムリチウムを用いて行うか、ベンゼン、ト
ルエンなどの溶媒中、水素化ビス(2−メトキシエトキ
シ)アルミニウムナトリウムを用いて行われる。) can also be obtained by subjecting the compound represented by formula to a reduction reaction. For the reaction, when R is hydrogen or lower alkyl,
For example, by using sodium borohydride in a solvent such as methanol or ethanol, or if R is lower alkoxy, using lithium aluminum hydride in tetrahydrofuran, or by hydrogenation in a solvent such as benzene or toluene. It is carried out using sodium bis(2-methoxyethoxy)aluminum.
一般式(1)の化合物で不斉炭素を有するものは通常よ
く知られた方法で光学的に活性なエナンチォマ一に分割
することができる。Compounds of general formula (1) having an asymmetric carbon can usually be separated into optically active enantiomers by well-known methods.
一般式(1)の化合物は常法により酸付加増法すること
ができる。The compound of general formula (1) can be subjected to acid addition using a conventional method.
一穀式(1)の化合物は、以下の実験から明らかな通り
鎮痛、解熱、消炎作用を有し、たとえば鎮痛、消炎剤と
して、およびその合成中間体として有用である。As is clear from the following experiments, the compound of Ikkoku formula (1) has analgesic, antipyretic, and antiinflammatory effects, and is useful, for example, as an analgesic and antiinflammatory agent, and as a synthetic intermediate thereof.
次に、一般式(1)の化合物の薬理作用を実験方法とと
もに示す。Next, the pharmacological action of the compound of general formula (1) will be shown together with experimental methods.
実験方法1
鎮痛作用(フエニルキノン法)
HendergchOtらの方法〔J.Pharmac
Ol.exp.Ther.、125巻237ページ(1
957年)〕によつた。Experimental method 1 Analgesic effect (phenylquinone method) HendergchOt et al.'s method [J. Pharmac
Ol. exp. Ther. , vol. 125, p. 237 (1
957)].
体重20y前後の雌性Ddマウス(群6匹)に試験化合
物を経口投与し、1時間後に0.02%フエニルキノン
溶液を0.2m1/20y腹腔内投与し、その後20分
間ストレツチ症状の頻度を観察し、対照群に対する抑制
率からプロピツト法によりED5O値を求めた。実験方
法2
消炎作用(紫外線紅斑法)
Winderらの方法〔Arch.int.Pharm
acOdyn.ll6巻261ページ(1958年)〕
によつた。The test compound was orally administered to female Dd mice (group of 6 mice) weighing around 20 y, and 1 hour later, 0.02% phenylquinone solution was administered intraperitoneally at 0.2 ml/20 y, and the frequency of stretching symptoms was observed for 20 minutes thereafter. The ED5O value was determined from the inhibition rate with respect to the control group by the propitt method. Experimental method 2 Anti-inflammatory effect (ultraviolet erythema method) Winder et al.'s method [Arch. int. Pharm
acOdyn. Volume ll6, page 261 (1958)]
I went to bed.
体重250〜450yのモルモツトを用い、あらかじめ
脱毛した側腹部に直径7m7!f)穴を3個あてたゴム
板をあて、600Wの水銀ランプで15?の距離から8
0秒間照射した。2時間後、紅斑形成の程度をWind
erらの評点方法に準じて採点し、その評点合計が1.
5またはそれ以下を有効とし、有効率を求めた。Using a guinea pig weighing 250 to 450 years, a diameter of 7 m7 is placed on the flank that has been previously depilated. f) Place a rubber plate with 3 holes on it and use a 600W mercury lamp for 15? 8 from a distance of
Irradiated for 0 seconds. After 2 hours, reduce the degree of erythema formation.
Scoring was performed according to the scoring method of er et al., and the total score was 1.
A value of 5 or less was considered effective, and the effectiveness rate was determined.
なお、試験化合物液は照射1時間前と直後に半量ずつ(
全量で10m1/Kg)経口投与した。実験方法3
抗浮腫作用(カラゲニン法)
Winterらの方法〔PrOc.SOc.Exptl
.BiOl.Med.lll巻544ページ(1971
年)〕によつた。In addition, half the test compound solution was added one hour before and immediately after irradiation (
The total amount was 10 ml/Kg) orally. Experimental method 3 Anti-edema effect (carrageenan method) Winter et al.'s method [PrOc. SOc. Exptl
.. BiOl. Med. Volume llll, page 544 (1971
2000)].
体重1507前後のDOnr37Uラツト(一群5匹)
に試験化合物液を経口投与(25m1/Kg)し、1時
間後1%カラゲニン0.05m1を右後肢足踏皮下に注
射し、一定時間後に足容積を測定し、カラゲニン投与前
の足容積に対する増加百分率を算出し、対照群に対する
抑制率を求めた。この抑制率は2〜3回の繰り返し実験
の平均値で示した。以上の実験の結果を第1表にまとめ
ると次の通りである。表中の試験化合物Aは次の通りで
ある。DOnr37U rats weighing around 1507 kg (5 rats per group)
The test compound solution was orally administered (25 ml/Kg), and 1 hour later, 0.05 ml of 1% carrageenan was subcutaneously injected into the right hind paw, and the paw volume was measured after a certain period of time to determine the increase in paw volume from before carrageenan administration. The percentage was calculated to determine the inhibition rate relative to the control group. This inhibition rate was shown as the average value of 2 to 3 repeated experiments. The results of the above experiments are summarized in Table 1 as follows. Test compound A in the table is as follows.
A:2−〔4−(イミダゾ〔2・1−b〕チアゾール−
6−イル)フエニル〕−1−プロパノーノレー般式(1
)の化合物またはその酸付加塩を医薬として用いる場合
、それ自体あるいは適宜の薬埋的は許容される担体、賦
形剤、希釈剤と混合し、粉末、顆粒、錠斉カプセル剤、
坐剤、注射剤などの形態で経口的または非経口的に投与
することができる。A: 2-[4-(imidazo[2.1-b]thiazole-
6-yl)phenyl]-1-propanolet general formula (1
) or its acid addition salt is used as a medicine, either by itself or in a suitable pharmaceutical form, mixed with acceptable carriers, excipients, and diluents, and prepared into powders, granules, tablets, capsules,
It can be administered orally or parenterally in the form of suppositories, injections, etc.
投与量は症状などによつて異なるが、50〜150即が
好ましい。以下に実施例を挙げて、本発明を具体的に説
明する。Although the dosage varies depending on the symptoms, it is preferably 50 to 150 doses. The present invention will be specifically explained below with reference to Examples.
実施例 1
2−(4−クロルアセチルフエニル)プロピルアセテー
ト127yおよび2−アミノチアゾール10yをアルコ
ール100TII.1中に加え、水浴上4時間加熱還流
する。Example 1 2-(4-chloroacetylphenyl)propyl acetate 127y and 2-aminothiazole 10y were mixed with alcohol 100TII. 1 and heated under reflux on a water bath for 4 hours.
アルコールを減圧下に濃縮し、酢酸エチル200m1で
抽出し、水洗後、硫酸マグネシウムで乾燥する。減圧下
に濃縮して得られた結晶をイソプロパノールから再結晶
すると、融点100〜103℃の無色針状晶である2−
〔4−(イミダゾ〔2・1−b〕チアゾール−6−イル
)フエニル〕プロピルアセテート8.07が得られる。
実施例 2
2−〔4−(イミダゾ〔2・1−b〕チアゾール−6−
イル)フエニル〕プロピルアセテート8.07をアルコ
ール50m1中に加え、これに20%水酸化ナトリウム
溶液10m1を加え、室温で約1時間放置する。The alcohol is concentrated under reduced pressure, extracted with 200 ml of ethyl acetate, washed with water, and dried over magnesium sulfate. When the crystals obtained by concentrating under reduced pressure are recrystallized from isopropanol, 2-
8.07 of [4-(imidazo[2.1-b]thiazol-6-yl)phenyl]propyl acetate is obtained.
Example 2 2-[4-(imidazo[2.1-b]thiazole-6-
8.07 g of phenyl]propyl acetate is added to 50 ml of alcohol, 10 ml of 20% sodium hydroxide solution is added thereto, and the mixture is allowed to stand at room temperature for about 1 hour.
減圧下に濃縮し、生じた結晶を沢取し、水洗後、アルコ
ールから再結晶すると、融点176〜178℃の無色針
状晶である2一〔4−(イミダゾ〔2・1−b〕チアゾ
ール−6一イル)フエニル〕−1−プロパノール4.5
7が得られる。実施例 3
4−(イミダゾ〔2・1−b〕チアゾール−6−イル)
フエニル酢酸エチル8.67をテトラヒドロフラン20
0m1に溶解した溶液を水素化アルミニウムリチウム2
.37をテトラヒドロフラン50m1に懸濁した液中に
氷冷下滴下する。Concentrate under reduced pressure, collect a lot of the formed crystals, wash with water, and recrystallize from alcohol to obtain 2-[4-(imidazo[2,1-b]thiazole), which is a colorless needle crystal with a melting point of 176-178°C. -6-yl)phenyl]-1-propanol 4.5
7 is obtained. Example 3 4-(imidazo[2.1-b]thiazol-6-yl)
Phenyl ethyl acetate 8.67 to tetrahydrofuran 20
Lithium aluminum hydride solution dissolved in 0ml
.. 37 was suspended in 50 ml of tetrahydrofuran and added dropwise under ice cooling.
室温で約1時間保つた後、水浴上1時間加熱還流する。
反応液を氷冷し、ロツセル塩飽和水溶液を滴下して過剰
の水素化リチウムアルミニウムを分解する。テトラヒド
ロフラン層を分取し、減圧下に濃縮後、生じた結晶をイ
ソプロパノールから再結晶すると、融点144〜145
℃の4−(イミダゾ〔2・1一b〕チアゾ;ル一6−イ
ル)フエネチルアルコール4.5yが得られる。以下、
同様にして次の化合物が合成される。After being kept at room temperature for about 1 hour, it is heated under reflux on a water bath for 1 hour.
The reaction solution is ice-cooled, and a saturated aqueous solution of Rothsell's salt is added dropwise to decompose excess lithium aluminum hydride. The tetrahydrofuran layer was separated, concentrated under reduced pressure, and the resulting crystals were recrystallized from isopropanol to give a melting point of 144-145.
4.5y of 4-(imidazo[2.11b]thiazol;ru-6-yl)phenethyl alcohol at a temperature of 4.5y is obtained. below,
The following compounds are synthesized in the same manner.
Claims (1)
ルカルボニルを示す。 )で表わされるアルコール誘導体またはその酸付加塩。[Claims] 1 Alcohol derivatives or acid addition salts thereof represented by the general formula ▲ Numerical formulas, chemical formulas, tables, etc. ▼ (In the formula, A represents lower alkylene and X represents hydrogen or lower alkyl carbonyl.) .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58195048A JPS5940835B2 (en) | 1983-10-17 | 1983-10-17 | alcohol derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58195048A JPS5940835B2 (en) | 1983-10-17 | 1983-10-17 | alcohol derivative |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51005284A Division JPS5929594B2 (en) | 1976-01-19 | 1976-01-19 | alcohol derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59112991A JPS59112991A (en) | 1984-06-29 |
| JPS5940835B2 true JPS5940835B2 (en) | 1984-10-03 |
Family
ID=16334674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58195048A Expired JPS5940835B2 (en) | 1983-10-17 | 1983-10-17 | alcohol derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5940835B2 (en) |
-
1983
- 1983-10-17 JP JP58195048A patent/JPS5940835B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59112991A (en) | 1984-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5464872A (en) | Arylalkyl (thio) amides | |
| PT100178A (en) | PROCESS FOR THE PREPARATION OF 1-AZABICYCLO (3.2.2) NONAN-3-AMINE DERIVATIVES | |
| US5236940A (en) | Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation | |
| JPS582936B2 (en) | 5↓-Production method of aroylpyrroleacetic acid and its salts | |
| JPH0276855A (en) | Quinoline ether alkanoic acid | |
| US4365076A (en) | Process for the preparation of cycloalkylidenemethylphenylacetic acid derivatives | |
| US4338323A (en) | Piperidylbenzimidazolinone derivatives | |
| JPH09143075A (en) | Cell adhesion inhibitor | |
| JPH0747585B2 (en) | Isoxazole derivative | |
| JPS59205339A (en) | Leucotriene antagonist | |
| JPS6363533B2 (en) | ||
| JPS5910675B2 (en) | Aralkylamine derivatives | |
| Yamato et al. | Synthesis and structure-activity relationship of spiro [isochromanpiperidine] analogs for inhibition of histamine release. 1 | |
| US4923880A (en) | 4,5,6,7-Tetrahydroisothiazolo (4,5-c) pyridine derivatives | |
| US3127401A (en) | Z-benzyl-j | |
| JPH0687843A (en) | New heterocyclic compounds, their production and medicinal compositions containing them | |
| JPS5940835B2 (en) | alcohol derivative | |
| JPS6399057A (en) | Glycine derivative | |
| JPS5929594B2 (en) | alcohol derivative | |
| US4432991A (en) | Therapeutically active 3-amino-1-phenyl(and substituted phenyl)-2-pyrazolines | |
| JPS584699B2 (en) | Substituted phenylacetic acid derivatives and their production method | |
| US4243665A (en) | 2-Heterocyclylalkyl-6-methoxy-naphthalenes | |
| US4093814A (en) | Esters of 4-[3-(substituted amino)-2-hydroxypropoxy]-5,6,7,8-tetrahydro-1,6,7-naphthalenetriols | |
| US3206480A (en) | Dibenzofuranamines | |
| US3281468A (en) | beta-phenyl-beta-hydroxyethylamines |